GO:1902564 negative regulation of neutrophil activation: Immune Signaling Checkpoints, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902564 (negative regulation of neutrophil activation) is a biological process that stops, prevents, or reduces the frequency, rate, or extent of neutrophil activation.
• Negative regulation of immune signaling pathways in neutrophils is essential to prevent excessive inflammation and tissue damage.
• Key negative regulators include CD44, CD300f, PKB/Akt, PD-L1, Ncf1, and platelet-derived extracellular vesicles.
• Dysregulation of this process is implicated in skin inflammation, aortic aneurysm, colorectal tumorigenesis, and hepatocellular carcinoma metastasis.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators in neutrophil biology.
• Targeting negative regulation of neutrophil activation is a promising therapeutic strategy in inflammatory diseases and cancer.
Description
Neutrophils are the most abundant circulating leukocytes and act as first responders to infection and injury. Their activation must be tightly controlled to avoid collateral tissue damage. GO:1902564, negative regulation of neutrophil activation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of neutrophil activation. This term is critical for understanding how the immune system balances effective pathogen clearance with prevention of chronic inflammation and autoimmunity. Research has identified multiple negative regulators that operate through distinct mechanisms, including modulation of apoptosis, receptor signaling, and cell-cell interactions. For example, activation of CD44 on epithelial cells negatively regulates epithelium-neutrophil interactions, while ceramide-CD300f binding inhibits lipopolysaccharide-induced skin inflammation. The PKB/Akt pathway modulates neutrophil apoptosis, thereby influencing the lifespan and activation state of these cells. More recently, platelet mitochondrial transfer via extracellular vesicles was shown to modulate neutrophil phenotype and function, and Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm by activating the STING pathway. These findings underscore the importance of negative regulation in maintaining immune homeostasis. This article provides a research-grade overview of GO:1902564, integrating authoritative QuickGO data with verified PubMed literature to support researchers studying neutrophil biology, inflammation, and therapeutic development.
negative regulation of neutrophil activation At A Glance
| GO ID | GO:1902564 |
|---|---|
| GO term | negative regulation of neutrophil activation |
| Ontology | biological_process |
| Synonym | down regulation of neutrophil activation, down-regulation of neutrophil activation, downregulation of neutrophil activation, inhibition of neutrophil activation |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of neutrophil activation |
| Related processes | Regulation of immune signaling pathways, apoptosis, cell-cell interactions |
| Key negative regulators | CD44, CD300f, PKB/Akt, PD-L1, Ncf1, platelet extracellular vesicles |
| Disease relevance | Skin inflammation, aortic aneurysm, colorectal tumorigenesis, hepatocellular carcinoma |
What Is GO:1902564?
GO:1902564, negative regulation of neutrophil activation, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of neutrophil activation. This includes molecular mechanisms that dampen signaling cascades, promote apoptosis, or inhibit effector functions of neutrophils, thereby preventing excessive inflammatory responses.
Why Is negative regulation of neutrophil activation Important in Cell Biology?
Negative regulation of neutrophil activation is essential for preventing excessive inflammation and tissue damage while maintaining effective host defense. Dysregulation of this process contributes to a wide range of pathologies, including chronic inflammatory diseases, autoimmune conditions, and cancer progression. Understanding the molecular mechanisms that restrain neutrophil activation can reveal therapeutic targets for modulating immune responses in disease settings.
• Prevents collateral tissue damage during infection and inflammation.
• Controls neutrophil lifespan through modulation of apoptosis.
• Regulates epithelium-neutrophil interactions via CD44 activation.
• Inhibits lipopolysaccharide-induced skin inflammation through ceramide-CD300f binding.
• Modulates neutrophil phenotype and function via platelet mitochondrial transfer.
• Protects against angiotensin II-induced aortic aneurysm and dissection through Ncf1 and STING pathway regulation.
• Restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis.
• Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy.
• Provides potential therapeutic targets for inflammatory diseases and cancer.
• Guides development of CRISPR-based models to study causal roles of negative regulators.
What Happens During negative regulation of neutrophil activation?
Initiation by Negative Regulators
In simple terms: Certain molecules act as brakes on neutrophil activation.
Negative regulation of neutrophil activation begins when specific receptors or signaling molecules engage to dampen activating signals. For instance, activation of CD44 on epithelial cells negatively regulates epithelium-neutrophil interactions, reducing neutrophil adhesion and activation. Similarly, ceramide binding to CD300f inhibits lipopolysaccharide-induced skin inflammation by suppressing neutrophil activation. These initiators set the stage for downstream inhibitory cascades.
Modulation of Intracellular Signaling Pathways
In simple terms: Inside the neutrophil, signaling pathways are adjusted to reduce activation.
Intracellular pathways such as PKB/Akt modulate neutrophil apoptosis, thereby influencing the lifespan and activation state of neutrophils. Negative regulation of immune signaling pathways in neutrophils involves multiple checkpoints that prevent excessive responses. For example, Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm by activating the STING pathway, indicating that Ncf1 normally restrains inflammatory signaling. These signaling adjustments reduce the frequency and extent of neutrophil activation.
Intercellular Communication and Extracellular Vesicles
In simple terms: Other cells can send signals to calm neutrophils down.
Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function, representing an intercellular mechanism of negative regulation. This communication can alter neutrophil activation states and effector functions. Additionally, PD-L1 restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis, indirectly influencing neutrophil activation in the tumor microenvironment.
Resolution of Activation and Return to Homeostasis
In simple terms: The neutrophil returns to a resting state, preventing damage.
Ultimately, negative regulation leads to reduced neutrophil activation, promoting resolution of inflammation and return to homeostasis. This step involves termination of activating signals, induction of apoptosis, and clearance of activated neutrophils. Failure of this resolution can lead to chronic inflammation and tissue damage, as seen in aortic aneurysm and hepatocellular carcinoma metastasis.
Key Genes Involved in GO:1902564 negative regulation of neutrophil activation
The following genes and proteins are key players in negative regulation of neutrophil activation, supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD44 | Negatively regulates epithelium-neutrophil interactions | Studied in cell adhesion and inflammation |
| CD300f | Inhibits LPS-induced skin inflammation via ceramide binding | Target for skin inflammation research |
| PKB/Akt | Modulates neutrophil apoptosis | Regulates neutrophil lifespan |
| PD-L1 | Restrains Treg cells to suppress inflammation-driven tumorigenesis | Cancer immunology and inflammation |
| Ncf1 | Protects against aortic aneurysm by inhibiting STING pathway | Cardiovascular inflammation research |
| STING | Pathway activated upon Ncf1 knockout, exacerbating aneurysm | Innate immune signaling |
| Platelet extracellular vesicles | Modulate neutrophil phenotype and function | Cell-cell communication |
| PD-1 | Immune checkpoint receptor on Treg cells | Tumor immunology |
| Nrp1 | Marker on Treg cells | Treg biology |
| Ferroptosis regulators | Link inflammation to hepatocellular carcinoma metastasis | Cancer therapy |
| Sorafenib targets | Enhance efficacy when combined with ferroptosis inhibition | HCC treatment |
| Immune signaling checkpoints | Negative regulation of neutrophil function | Broad inflammation research |
| Apoptosis regulators | Control neutrophil lifespan | Cell death research |
| Adhesion molecules | Mediate epithelium-neutrophil interactions | Cell adhesion |
| Ceramide | Lipid mediator binding CD300f | Lipid signaling |
| Mitochondria | Transferred via EVs to modulate neutrophils | Metabolism and immunity |
| STING pathway components | Innate immune activation | Aneurysm and inflammation |
How Is negative regulation of neutrophil activation Regulated?
Negative regulation of neutrophil activation is controlled by multiple signaling pathways. PKB/Akt modulation affects neutrophil apoptosis and lifespan. Negative regulation of immune signaling pathways in neutrophils involves checkpoints that prevent excessive activation. Ncf1 deficiency leads to STING pathway activation, exacerbating aortic aneurysm, indicating that Ncf1 normally restrains this pathway. PD-L1 restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis, indirectly regulating neutrophil activation in the tumor microenvironment. Platelet mitochondrial transfer via extracellular vesicles also modulates neutrophil phenotype and function.
negative regulation of neutrophil activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD300f | Skin inflammation | Knockout mouse model |
| Ncf1 | Aortic aneurysm and dissection | Smooth muscle cell-specific knockout |
| PD-L1 | Colorectal tumorigenesis | Knockout or overexpression in tumor models |
| Ferroptosis regulators | Hepatocellular carcinoma metastasis | Xenograft models with sorafenib |
| PKB/Akt | Neutrophil apoptosis dysregulation | Knockout or point mutation |
Inflammatory Skin Diseases
Ceramide-CD300f binding inhibits lipopolysaccharide-induced skin inflammation, highlighting the role of negative regulation of neutrophil activation in preventing excessive skin inflammation. Dysregulation of this pathway may contribute to chronic inflammatory skin conditions.
Cardiovascular Diseases
Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm and dissection by activating the STING pathway, demonstrating that loss of negative regulation of neutrophil activation can promote vascular pathology.
Cancer
PD-L1 restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis, linking negative regulation of neutrophil activation to cancer prevention. Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy, suggesting that modulating neutrophil activation can improve cancer therapy.
From negative regulation of neutrophil activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Ncf1 negatively regulate neutrophil activation in aortic aneurysm? | Smooth muscle cell-specific Ncf1 knockout mouse |
| How does CD300f inhibit skin inflammation? | CD300f knockout or knock-in mouse |
| What is the role of PD-L1 in colorectal tumorigenesis? | PD-L1 knockout or overexpression in mouse models |
| How does PKB/Akt modulate neutrophil apoptosis? | PKB/Akt point mutation or knockout in neutrophils |
| Can ferroptosis inhibition enhance sorafenib efficacy? | Hepatocellular carcinoma xenograft with ferroptosis regulators knockout |
| How do platelet extracellular vesicles modulate neutrophils? | In vitro EV transfer assays with tagged mitochondria |
How to Study the negative regulation of neutrophil activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Identify negative regulators |
| RNA-seq | Transcriptional changes | Profile immune responses |
| Proteomics | Protein abundance and modifications | Study signaling pathways |
| Flow cytometry | Neutrophil activation markers | Assess activation states |
| In vivo inflammation models | Disease phenotypes | Test gene function in disease |
| Extracellular vesicle transfer assays | Intercellular communication | Study platelet-neutrophil interactions |
| Apoptosis assays | Cell death | Measure neutrophil lifespan |
| Ferroptosis assays | Lipid peroxidation | Link inflammation to cancer |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that negatively regulate neutrophil activation. For example, Ncf1 knockout in smooth muscle cells exacerbated aortic aneurysm, demonstrating the power of CRISPR to uncover causal roles.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon modulation of negative regulators. Studies on PD-L1 and Treg cells utilized such approaches to link immune regulation to tumorigenesis.
Functional Assays for Neutrophil Activation
Neutrophil activation can be measured by oxidative burst, degranulation, and cytokine release. CD44 activation was shown to negatively regulate epithelium-neutrophil interactions using such assays.
In Vivo Inflammation Models
Mouse models of skin inflammation, aortic aneurysm, and cancer are used to study negative regulation of neutrophil activation. Ceramide-CD300f binding was tested in LPS-induced skin inflammation models, and Ncf1 knockout was studied in angiotensin II-induced aortic aneurysm models.
How CRISPR Can Be Used to Study GO:1902564 negative regulation of neutrophil activation
Knockout
CRISPR knockout of negative regulators such as Ncf1 or CD300f can reveal their causal role in neutrophil activation and disease. Ncf1 knockout in smooth muscle cells exacerbated aortic aneurysm, demonstrating the utility of knockout models.
Point Mutation
Point mutations can dissect specific signaling domains. For example, mutations in PKB/Akt can modulate neutrophil apoptosis, allowing precise structure-function studies.
Knock-in
Knock-in of tagged or reporter genes enables tracking of negative regulators in vivo. Tagged CD300f or PD-L1 could be used to monitor expression and localization during inflammation.
Overexpression
Overexpression of negative regulators such as PD-L1 or CD44 can suppress neutrophil activation and inflammation. PD-L1 overexpression restrains Treg cells and suppresses colorectal tumorigenesis.
How EDITGENE Supports negative regulation of neutrophil activation Research
Researchers studying negative regulation of neutrophil activation-related genes often need to determine whether a candidate gene is causally involved in restraining neutrophil activation or is merely a bystander. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of neutrophil activation research.
Frequently Asked Questions About negative regulation of neutrophil activation
What is negative regulation of neutrophil activation?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of neutrophil activation, as defined by GO:1902564.
What genes are involved in negative regulation of neutrophil activation?
Key genes include CD44, CD300f, PKB/Akt, PD-L1, Ncf1, and components of platelet extracellular vesicles.
How does CD44 negatively regulate neutrophil activation?
Activation of CD44 on epithelial cells negatively regulates epithelium-neutrophil interactions, reducing neutrophil adhesion and activation.
What is the role of CD300f in skin inflammation?
Ceramide-CD300f binding inhibits lipopolysaccharide-induced skin inflammation by suppressing neutrophil activation.
How does Ncf1 protect against aortic aneurysm?
Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm by activating the STING pathway, indicating Ncf1 normally restrains this pathway.
Can PD-L1 regulate neutrophil activation in cancer?
PD-L1 restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis, indirectly influencing neutrophil activation.
What methods are used to study negative regulation of neutrophil activation?
CRISPR knockout, RNA-seq, proteomics, flow cytometry, and in vivo inflammation models are commonly used.
How does PKB/Akt modulate neutrophil apoptosis?
PKB/Akt activation regulates neutrophil apoptosis, thereby influencing neutrophil lifespan and activation state.
What is the link between ferroptosis and neutrophil activation in cancer?
Targeting ferroptosis-elicited inflammation suppresses hepatocellular carcinoma metastasis and enhances sorafenib efficacy, suggesting a role for neutrophil activation.
How can CRISPR models help study negative regulation of neutrophil activation?
CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators in neutrophil biology.
Conclusion
GO:1902564, negative regulation of neutrophil activation, is a critical biological process that maintains immune homeostasis by preventing excessive neutrophil activation. Key negative regulators such as CD44, CD300f, PKB/Akt, PD-L1, and Ncf1 have been implicated in diverse diseases including skin inflammation, aortic aneurysm, and cancer. Understanding these mechanisms offers therapeutic opportunities, and CRISPR-based models are indispensable for functional validation. EDITGENE provides comprehensive services to support research in this field.
References
- 1. Azcutia V et al.. 2017. Role of negative regulation of immune signaling pathways in neutrophil function.. J Leukoc Biol PMID: 29345376
- 2. Mu M et al.. 2024. Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy.. Cancer Res 84(6):841-854 PMID: 38231484
- 3. Rane MJ et al.. 2009. Regulation of neutrophil apoptosis by modulation of PKB/Akt activation.. Front Biosci (Landmark Ed) 14(7):2400-12 PMID: 19273208
- 4. Si-Tahar M et al.. 2001. Negative regulation of epithelium-neutrophil interactions via activation of CD44.. Am J Physiol Cell Physiol 280(3):C423-32 PMID: 11171560
- 5. Liu H et al.. 2024. Ncf1 knockout in smooth muscle cells exacerbates angiotensin II-induced aortic aneurysm and dissection by activating the STING pathway.. Cardiovasc Res 120(9):1081-1096 PMID: 38639325
- 6. Allan HE et al.. 2025. Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function.. J Thromb Haemost 23(11):3665-3677 PMID: 40846030
- 7. Shiba E et al.. 2017. Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation.. J Biol Chem 292(7):2924-2932 PMID: 28073916
- 8. Poschel DB et al.. 2024. PD-L1 restrains PD-1(+)Nrp1(lo) Treg cells to suppress inflammation-driven colorectal tumorigenesis.. Cell Rep 43(10):114819 PMID: 39368087
